Definium’s psychedelic prospects brighten further on Phase III success

Phase 3positiveDT120Positive

AI Analysis

Summary

Definium's DT120 has demonstrated positive Phase III results in both generalized anxiety disorder and major depressive disorder, advancing its potential entry into the neuropsychiatric market.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

DT120 posted positive results in both GAD and MDD Phase III trials

Importance:7/10

Sentiment:

0.80

psychedelicpsychiatryPhase 3positive resultsGADMDD

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 13, 2026 8:56 AM

Read Original